Annovis Bio Granted U.S. Patent for Traumatic Brain Injury Treatment Using Buntanetap

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company, has been granted a U.S. patent for the use of its lead drug candidate, buntanetap, in treating traumatic brain injury (TBI). The newly issued U.S. Patent No. 12,042,482 specifically covers methods for treating TBI and preventing nerve cell death using buntanetap, marking a significant expansion of Annovis Bio's intellectual property portfolio.

This patent issuance comes at a critical time, as TBI remains one of the leading causes of death and disability in the United States, with an annual death rate exceeding 70,000. The potential impact of this development on public health and the medical community could be substantial, offering new hope for TBI patients and their families.

Buntanetap, formerly known as Posiphen, is a novel drug that targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43. By inhibiting the translation of these proteins, buntanetap has shown promise in improving synaptic transmission, enhancing axonal transport, reducing neuroinflammation, and protecting nerve cells from death.

The newly granted patent adds to Annovis Bio's diverse portfolio, which already includes various patents and applications for using buntanetap in treating both acute and chronic neurodegenerative diseases and mental illnesses. This expanded protection could potentially accelerate the development and commercialization of buntanetap for TBI treatment.

The journey to this patent began in 2016 when Annovis Bio initially filed for protection covering treatments for various nerve injuries, including TBI, stroke, and spinal cord injuries. The United States Patent and Trademark Office (USPTO) required the company to divide the application into individual patents, leading to the specific TBI treatment patent now granted.

This patent issuance strengthens Annovis Bio's position in the competitive neurodegenerative disease treatment market. As the company continues to advance buntanetap through clinical trials, the added patent protection could attract potential partners and investors, potentially accelerating the drug's path to market.

The broader implications of this development extend beyond Annovis Bio and into the field of neuroscience and TBI treatment. With limited effective treatments currently available for TBI, buntanetap's novel mechanism of action targeting multiple neurotoxic proteins could represent a significant advancement in addressing this critical medical need.

As research continues and clinical trials progress, the medical community and patients alike will be watching closely to see if buntanetap can deliver on its promise to provide a new and effective treatment option for TBI. The success of this drug could not only benefit TBI patients but also potentially open new avenues for treating other neurodegenerative conditions.

Investors and industry observers can find more information about Annovis Bio and its developments at https://ibn.fm/ANVS. As the company moves forward with its research and development efforts, the impact of this patent and the potential of buntanetap in treating TBI and other neurodegenerative diseases will likely remain a focal point for the biotech industry.